“Both companies have attractive profiles, but for different reasons. But what they have in common is good science that, if successful, will address a pressing medical need.” CEO Henry Skinner on investing in @AdaptivePhageTx and Venatorx Pharmaceuticals #AMR statnews.com/pharmalot/2022…

Landmark step: UK is poised to become the first country in the world to launch a new subscription payment model (the 'Netflix' model) for antibiotics that could reverse decades of decline in the category. #AMR #antibiotics #AntimicrobialResistance pharmaphorum.com/news/uk-launch…

ArrePath will be presenting at #ECCMID2022 'Therapeutics Pipeline Corner' 25th April, 1215-1315 Lisbon time. Please contact us for a meeting at arrepath.com/contact-us/ #AMR #antibiotics #machinelearning #AI

Our CEO, @DrLloyd_P, will be presenting at #ECCMID2022 during the Pipeline Corner session, 12:15 Lisbon time, Arena 2. If you're at ECCMID, come along! #amr #antimicrobialresistance #drugdiscovery #AI #ML

We are delighted to welcome Dr. @kylebarbary to our fast growing team at ArrePath. As Lead Data Scientist, Computer Vision, Kyle will apply new methods in computer vision and machine learning to drug discovery and optimisation applications. #computervision #ML #AI #drugdiscovery

“Conduct research today so we will have antibiotics tomorrow” – wise words from Kevin Outterson pharmaphorum.com/r-d/the-antimi… #AMR

A warm welcome to our new VP Microbiology, Dr Bret Benton! Head over to arrepath.com/about/ to meet the team and learn more about our strategy to discovery and develop new classes of anti-infectives. #drugdiscovery #ai #ml #antibiotics #amr #antimicrobialresistance #imaging

“We’re going to get this over the finish line.” Thank you Michael Bennet for your optimism and determination to see PASTEUR passed. #SquashSuperbugs

The US government’s BARDA & Wellcome will provide up to an additional $370M to CARB-X to support a portfolio of therapeutics, diagnostics and preventatives to address the global health threat of antimicrobial resistance #AMR. ➡️ Announcement: bit.ly/3a2WSkx

New CDC Report on impact of #COVID on #AMR: “This setback can and must be temporary. The COVID-19 pandemic has unmistakably shown us that antimicrobial resistance will not stop if we let down our guard; there is no time to waste,” #AntimicrobialResistance cdc.gov/drugresistance…

A warm welcome to Dr Paul Lukacs from all of us at ArrePath! We look forward to working with Paul as we continue to deliver on our mission to harness the power of imaging technologies and AI / ML in the discovery of new anti-infectives. #AI #ML #drugdiscovery #antiinfectives

We're hiring! Fabulous opportunities for early career Data Scientists and Computer Vision scientists to join a great team in a great company, applying the latest approaches in AI / ML in drug discovery. Please visit arrepath.com/careers/ for more details. #AI #ML #Hiring

At ArrePath, we believe our team is everything. As part of our season introducing our team members, say hello to Gayatri, who joined ArrePath at the beginning of 2022. We continue to grow and hire, please visit: arrepath.com/careers/

A very warm welcome to our newest 'Arrenaut', Jenna Pellegrino! Jenna joins our Princeton NJ-based team where she will be implementing new AI / ML-enabled techniques for the discovery and optimisation of new classes of anti-infectives. ArrePath is hiring: lnkd.in/efbE6UrE

A very warm welcome to Erin Chinn, our newest Arrenaut! Erin joins our Data Science team and will apply her expertise in Computer Vision to further develop our AI/ML-enabled imaging platform and its application in drug discovery. #AI #ML #drugdiscovery #computervision #microscopy

Thrilled that John Alter, head of external affairs, is among the speakers at TrinityAMRaction Annual Antimicrobial Resistance Conference at Trinity College. Should be an insightful #AMR event! Learn more: eventbrite.com/e/trinity-amr-…

ArrePath has been chosen to present at MassBio's first #InnovationWeek! Join our CEO, @DrLloyd_P, who will provide a company overview and update on the application of our AI / ML enabled imaging platform in the discovery of new classes of antibacterials. bit.ly/InnovationWeek…

A warm welcome to our new SAB members Professors Connor W. Coley (MIT) and Paul Hergenrother (U of Illinois), joining Prof. Barbara Engelhardt (Stanford) and Todd Black (TB Alliance), chaired by our scientific founder Prof. Zemer Gitai zgitai (Princeton). Stella team! arrepath.com/arrepath-appoi…

ArrePath is looking forward to taking part in #BioInfect2023; Alderley Park, UK, 1st Feb 2023, where our CEO, @DrLloyd_P, will be presenting in the 'State of the AMR Nation' panel discussion bionow.co.uk/event/BIONOW14…

'The two public health crises - cancer and drug resistant infections - are deeply intertwined.' Without a plan to fight superbugs, the Cancer Moonshot will never achieve liftoff statnews.com/2023/08/03/ant… #AMR #antimicrobialresistance #antibiotics #cancer #cancermoonshot